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Apoptosis in malignant diseases
Goran R. Braju„kovi￿
ABSTRACT
Apoptosis is a special type of cell death essentially different from necrosis in nature and biological sig-
nificance. It is an active process of genetically regulated cell autodestruction and in most cases has a
homeostatic function. Apoptotic cells may be characterized by specific morphological and biochemical
changes. A great number of genes are known today, whose protein products take part in regulation of
the apoptotic process. Apoptosis or programmed cell death has been implicated in a wide range of
pathological conditions. Studies of the correlation of programmed cell death with proliferation and the
multistage carcinogenesis process are in the focus of modern research.  Mutations and deletions of
apoptotic genes play important roles in carcinogenesis, tumor growth, and tumor regression. This arti-
cle reviews the current knowledge on mutations of apoptosis genes involved in pathogenesis of human
cancers. Finally, we have recently summarized achievements in cancer therapy with a focus on the apop-
totic genes.
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APOPTOSIS IN MALIGNANT DISEASES
What is apoptosis - from the Greek: falling off
D
eath, along with growth and differentiation, is a critical part of the life cycle of a cell (1).
Apoptosis was the name given by Kerr, Wyllie and Currie in 1972, to morphologic
change culminating in cell death by process clearly distinct from necrosis (2,3).
Morphologically, apoptosis is characterized by nuclear and cytoplasmic condensation of
single cells (shrinkage) followed by loss of the nuclear membrane; fragmentation of nuclear
chromatin, and subsequent formation of multiple fragments of the nuclear material and
cytoplasm - apoptotic bodies (4,5). Recent data suggest that apoptosis or "cellular suicide"
is a set of ordered events that enables the selective removal of cells from tissue and is
essential for homeostasis and proper function of multicellular organisms (6). Cells may also
be eliminated by a number of other mechanisms including: autophagy, mitotic catastrophe,
dark cell death, paraptosis, chondroptosis, autoschisis, etc. It is important to recognize that
these types of cell death differ not only morphologically, but biochemically as well (7).
Biochemical features associated with apoptosis include internucleosomal cleavage of DNA,
leading to an oligonucleosomal "ladder", phosphatidylserine externalization and proteolytic
cleavage of a number of intracellular substrates (8). At the molecular level, the apoptotic
cell death machinery forms a complex cascade of ordered events, controlled by the regu-
lated expression of apoptosis - associated genes and proteins. The key components of this
self - destruction machinery are members of the caspase family. More than 10 caspases
have been identified. Some of them (e.g., caspase 2,8,9,10, and, probably, -11) are
involved in the initiation of apoptosis others (e.g., caspase 6 and 7) execute the death order
by destroying essential proteins in the cell. The caspase 3 is speculated to have a crucial
role in apoptosis and is responsible for the cleavage of many critical cellular substrates,
leading to characteristic morphological changes in apoptosis such as chromatin conden-
sation, nucleosomal DNA fragmentation and formation of apoptotic bodies (7,9,10). 
Two major apoptosis pathways have been identified (11). One major apoptotic pathway
involves cell surface death receptors that transmit an apoptotic signal on binding of a spe-
cific death ligand. The largest known family of death receptors is represented by tumor
necrosis factor receptors. Upon ligand binding an intracellular "death domain" (DD) of the
receptor interacts with a homolog domain in an adaptor protein which recruits caspases.
Fas (CD 95, Apo-1) is a transmembrane receptor protein. Binding of its natural ligand, Fas
ligand (FasL) triggers apoptosis. The apoptosis signal is transmitted via intracellular DD of
Fas. That domain interacts with homologous motif in the adaptor protein FADD (Fas-asso-
ciated DD protein). FADD protein also contains a DED domain (death effector domain), and
this, in turn, recruits pro - caspase 8, which binds via its DED. Via aggregation of two or
more procaspase 8 molecules, procaspase 8 becomes activated. Active caspase 8 can
then go on to trigger the apoptotic caspase cascade (8,12). 
A second major apoptotic pathway involves mitochondria. A great number of mitochondri-
al proteins take part in the regulation of apoptosis (13). Cytochrome c, a component of the
mitochondrial electron transfer chain, initiates caspase activation when released from mito-
chondria during apoptosis (14). Cytosolic cytochrome c forms an essential part of the
apoptosome, which is composed of cytochrome c, Apaf-1 and procaspase 9. Only the cas-
pase 9 bound to the apoptosome is able to efficiently cleave and activate downstream exe-
cutioner caspases such as caspase 3 (Figure 1) (13,14). 
The mitochondrial pathway is regulated by members of Bcl-2 protein family. The principal
mechanism by which Bcl-2 family proteins regulate apoptosis is probably by controlling
cytochrome c release. Some of these proteins (such as Bcl-2, Bcl Xl) are anti-apoptotic
while others (such as Bax, Bad and Bak) are proapoptotic. While the anti-apoptotic proteins
work to prevent cytochrome c release from mitochondria, the proapoptotic members play
a major role in initiating cytochrome c release (8).It is known that the Bcl-2 protein plays a role in the promotion of cell survival and in the
inhibition of apoptosis. The Bcl-2 protein prevents cytochrome c release (15,16).  Bcl-2 -
associated protein X (Bax) was the first proapoptotic protein isolated by co-immunoprecip-
itation with Bcl-2 which is primarily localized to the cytosol. Death signals direct Bax pro-
tein from the cytosol to the mitochondrial outer membrane. In the same time, Bak protein,
which resides in the mitochondrial membrane in an inactive form, will be activated.
Together they allow release of cytochrome c from the intermembrane space of the mito-
chondria (11,17,18). Early experiments showed that over expression of anti-apoptotic pro-
teins Bcl-2 or Bcl Xl could inhibit the proapoptotic activity of Bax. The mechanism by which
Bcl-2 blocks apoptosis is by preventing Bax relocation to the mitochondria (11,17).
Korsmayer and his associates showed that Bcl-2 and Bax proteins could make homo- and
heterodimers. The antiapoptotic effects of Bcl-2 protein is based on its possibility to bind
Bax protein in the heterodimer form, and in that way blocks making Bax/Bax proapoptotic
homodimers. The ratio of Bcl-2/Bax represents a cell autonomous rheostat that predeter-
mines a cells life or death response to an apoptotic stimulus (19). 
The p53 protein is a nuclear protein that functions as a transcription factor capable of reg-
ulating a range of downstream genes. The p53 tumor suppressor limits cellular prolifera-
tion by inducing cell cycle arrest and apoptosis in response to cellular stresses such as
DNA damage, hypoxia, and oncogene activation. Many apoptosis-related genes that are
transcriptionally regulated by p53 have been identified (12,20).
Apoptosis and tumorigenesis
Apoptosis has been implicated in a wide range of pathological conditions. Increased apop-
tosis has been associated with acute ischemic diseases, neurodegenerative diseases such
as Alzheimer’s and Parkinson’s diseases, AIDS, diabetes and hepatitis. Decreased apopto-
sis is involved in cancer and autoimmune disorders (21).
Malignant transformation is a process where genetic occurrences are accumulated. In the
recent past, molecular oncologists focused their studies primarily on the cellular pathways
controlling proliferation. Neoplastic disease was typically envisaged as resulting from
defects in these pathways leading to excess cell division (22). During the last 12 years,
however, overwhelming evidence has accumulated which suggests that the other side of
the balance - the rate of cell death - is just as important. Studies of the correlation of pro-
grammed cell death with proliferation and the multistage carcinogenesis process are in the
focus of modern research. Mutations and deletions of apoptotic genes play important roles
in carcinogenesis, tumor growth, and tumor regression (12). Alterations of genes along the
Fas-mediated apoptosis pathway have been reported in many human cancers. Mutations
of Fas gene are rare in primary gastric MALT lymphomas (5.6%) but occur in a subset of
primary gastric diffuse large B-cell lymphomas (14.3%) and suggest that these mutations
contribute to the pathogenesis of gastric lymphomas by rendering lymphocytes resistant to
apoptosis (23). Fas gene mutations were also detected in Mycosis fungoides (24);
Hodgkin’s disease (12); bladder cancer (12); plasmocytomas (25), etc.
Genetic alternations of the Bcl-2 gene have been identified in hematologic malignancies
(12). The pathogenesis of follicular lymphoma and chronic lymphocytic leukemia involves
the dysregulation of the Bcl-2 protein (26). The Bcl-2 was first identified at the chromoso-
mal breakpoint of t(14;18) in a human leukemia line and was later shown to be a common
event in follicular lymphoma (5). The clinical significance of this feature is still controver-
sial. Current analysis of Bcl-2 expression by multicolor flow cytometric assists in the diag-
nosis of follicular lymphoma in lymph node and bone marrow (27). Inhibition of apoptosis
and upregulation of the Bcl-2 protein are key elements of the pathophysiology of chronic
lymphocytic leukemia (28). Aberrant expression of Bcl-2 protein in CLL is associated with
poor response to chemotherapy and decreased overall survival (29).
Bax mutations were detected in about 50% of human colon carcinomas with a microsatel-
lite mutator phenotype (12). In one third of breast adenocarcinomas reduced Bax expres-
sion has been detected. Decreased Bax expression associated with increased expression
of the anti-apoptotic family members has been shown in tumors in colon cancer patients
(11). The p53 tumor suppressor proapoptotic protein as transcription factor prevents tumor
developments through induction cell cycle arrest and apoptosis. Around half of all human
tumors carry p53 mutation. From a clinical standpoint, mutations in p53 are usually a poor
prognostic indication in a variety of tumor types including gastrointestinal, hematopoietic,
breast, and genitourinary cancers (22). Other tumors that frequently contain p53 mutations
(melanoma, lung cancers, bladder and prostate cancer) often respond poorly to radiation
or chemotherapy (12). In general, p53 mutations are more frequent in aggressive disease
and are associated with poor survival (30).
Apoptosis and cancer therapy
Experimental studies, both in vitro and in vivo, have shown the capability of antineoplastic
agents to induce the process of apoptosis. Studies conducted up to now on various mod-
els systems (acute lymphoblastic leukemia, lymphomas, mycosis fungoides, breast can-
cer, lung cancer, etc.) have shown that the ability of antineoplastic agents to induce apop-
tosis of neoplastic transformed cells represent a positive prognostic parameter in the treat-
ment of malignity (21,31).  Also, cytotoxic therapy and immunotherapy of leukemia and
lymphoma predominantly mediates cell death through induction of apoptosis (32).  Last ten
years, resistance to antitumor treatment is also considered from the viewpoint of the loss
of the capability of a certain antineoplastic agent to induce apoptosis of malignant cell
(33,34). Many investigators are starting to exploit the recent discovers about apoptosis to
develop new treatments. Gene therapy is still experimental. It is being studies in clinical tri-
als (research studies with humans) for many different types of cancer and for other dis-
eases. Cancer gene therapy  (based on genetic differences between normal and trans-
formed cells) has interest in developing approaches to inactive oncogenes or replace non-
functioning tumor suppressor genes. Transfer of various tumor suppressor genes directly
to cancer cells has been demonstrated to suppress tumor growth via induction of apopto-
sis and, in some cases, with evidence for bystander effects. Various studies also have
shown that combination of tumor suppressor gene therapy with conventional anticancer
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Figure 1. Induction of apoptosis via the mitochondrial pathwaytherapy can yield synergistic therapeutic benefits (35). Several therapy strategies have been
designed to restore p53 function in human tumors, including p53 gene therapy, reactivation
of mutant p53 and activation of wt p53 by inhibition of the p53 antagonist MDM 2 (30). The
first work with p53 gene therapy was conducted by Jack Roth and colleagues. They report-
ed the results of the first clinical trials using p53 delivered by a retrovirus vector to treat
patients with non-small-cell lung cancer who had failed other treatments. The recombinant
adenovirus was administered intratumorally and caused no toxic side effects up to 5
months later. Wild - type (wt) p 53 was detected in lung biopsy by in situ hybridization and
PCR amplification, and apoptosis was increased in posttreatment biopsy samples (36).
Furthermore, combined treatment of head and neck cancer with p53 gene replacement and
chemotherapy achieved a high proportion of complete response. By 6 months, none of the
responding tumors had progressed, whereas all tumors treated with chemotherapy alone
had progressed (12).
Because many tumor suppressors are currently known to function in the mediation of apop-
tosis, with p53 being a prime example, another strategy for cancer gene therapy has been
designed to introduce directly proapoptotic genes into tumor cells. Two groups of apopto-
sis inducing genes have been extensively studies: the proapoptotic members of the Bcl-2
gene family and the Fas death receptor members (37). Several laboratories have demon-
strated that gene transfer of FasL prevented growth and induced tumor regression in vivo.
The finding that gene transfer of FasL is able to generate a potent apoptotic response sug-
gests that molecular genetic intervention may be successful and must be further elucidat-
ed and pursued (9). Ad-Bax (adenoviruses with Bax gene) infection of human lung cancer
cell lines, both in vitro and in vivo caused apoptosis that was independent of endogenous
p53 status. Interestingly, lung cancer cell line resistant to Ad-p53 were susceptible to apop-
tosis following Ad-Bax (37).
Over expression of anti apoptotic Bcl-2 family members can promote tumorigensis and
chemoresistance, suggesting that functional inhibition of these protein might be lethal to
cancer cells (5). Bcl-2 has proved a provocative target for therapeutic intervention with the
aim of inducing apoptosis of malignant cells. Reduction of Bcl-2 level using antisense treat-
ment or intracellular expression of anti-Bcl-2 antibody may render tumor cells susceptible
to drug induced apoptosis (9). Bcl-2 antisense oligonucleotide therapy in patients with non-
Hodgkin’s lymphoma showed first positive effect. Recent results of a Phase I trial of a 14-
day continuous infusion of an 18-mer phosphorothioate oligonucleotides to first six codons
of the Bcl-2 open reading frame (G3139) have shown minimal toxicity ands some evidence
of antitumor activity. This oligonucleotide has also been used in phase I and II trials in com-
bination with dacarbazine for the treatment of melanoma resulting in 40% reduction in Bcl-
2 protein levels and an increase in tumor cell apoptosis as well as a considerable increase
in the apoptotic response to dacarbazine (38,39). The reduction in Bcl-2 gene expression
used antisense therapy was associated with increase in Bax gene and increased apoptosis
in CLL cells (40). Caspases seem to be the key executioners of apoptosis, and thus, rep-
resent an attractive target for therapeutic intervention. Modulation of caspase activity is cur-
rently the focus of both commercial and academic research. The team of company "Maxim
Pharmaceuticals" created "small molecule" caspase activator called MX-2060. As a poten-
tial anticancer agent, MX-2060 treated in human cancer xenograft animal models (39).
The near future of cancer therapy will most likely rely on the combined application of apop-
tosis - sensitizing strategies described above, and conventional radio- and chemotherapy.
Unfortunately, the fundamental problem still remains - How do we selectively activate apop-
tosis in an intrinsically resistant tumor cell?
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